NASDAQ:NEXI

NexImmune Competitors

$18.67
+0.31 (+1.69 %)
(As of 04/20/2021 11:17 AM ET)
Add
Compare
Today's Range
$18.67
Now: $18.67
$18.67
50-Day Range
$17.85
MA: $20.50
$25.91
52-Week Range
$17.06
Now: $18.67
$28.00
Volume2 shs
Average Volume135,191 shs
Market Capitalization$424.89 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

NexImmune (NASDAQ:NEXI) Vs. BCAB, CGEM, SBTX, NRIX, EWTX, and KNTE

Should you be buying NEXI stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to NexImmune, including BioAtla (BCAB), Cullinan Oncology (CGEM), Silverback Therapeutics (SBTX), Nurix Therapeutics (NRIX), Cricut (EWTX), and Kinnate Biopharma (KNTE).

NexImmune (NASDAQ:NEXI) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation and analyst recommendations.

Analyst Ratings

This is a summary of recent ratings and price targets for NexImmune and BioAtla, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NexImmune00303.00
BioAtla00403.00

NexImmune currently has a consensus price target of $33.3333, indicating a potential upside of 78.54%. BioAtla has a consensus price target of $58.00, indicating a potential upside of 23.72%. Given NexImmune's higher probable upside, equities research analysts plainly believe NexImmune is more favorable than BioAtla.

Profitability

This table compares NexImmune and BioAtla's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NexImmuneN/AN/AN/A
BioAtlaN/AN/AN/A

Valuation and Earnings

This table compares NexImmune and BioAtla's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NexImmuneN/AN/AN/AN/AN/A
BioAtlaN/AN/AN/AN/AN/A

Cullinan Oncology (NASDAQ:CGEM) and NexImmune (NASDAQ:NEXI) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk and analyst recommendations.

Profitability

This table compares Cullinan Oncology and NexImmune's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cullinan OncologyN/AN/AN/A
NexImmuneN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Cullinan Oncology and NexImmune, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cullinan Oncology01302.75
NexImmune00303.00

Cullinan Oncology currently has a consensus price target of $48.75, indicating a potential upside of 51.16%. NexImmune has a consensus price target of $33.3333, indicating a potential upside of 78.54%. Given NexImmune's stronger consensus rating and higher probable upside, analysts clearly believe NexImmune is more favorable than Cullinan Oncology.

Earnings & Valuation

This table compares Cullinan Oncology and NexImmune's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cullinan OncologyN/AN/AN/AN/AN/A
NexImmuneN/AN/AN/AN/AN/A

Summary

NexImmune beats Cullinan Oncology on 2 of the 2 factors compared between the two stocks.

Silverback Therapeutics (NASDAQ:SBTX) and NexImmune (NASDAQ:NEXI) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, dividends, earnings, institutional ownership and risk.

Valuation and Earnings

This table compares Silverback Therapeutics and NexImmune's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Silverback TherapeuticsN/AN/AN/AN/AN/A
NexImmuneN/AN/AN/AN/AN/A

Profitability

This table compares Silverback Therapeutics and NexImmune's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Silverback TherapeuticsN/AN/AN/A
NexImmuneN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings for Silverback Therapeutics and NexImmune, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Silverback Therapeutics00403.00
NexImmune00303.00

Silverback Therapeutics presently has a consensus target price of $50.25, indicating a potential upside of 40.72%. NexImmune has a consensus target price of $33.3333, indicating a potential upside of 78.54%. Given NexImmune's higher probable upside, analysts plainly believe NexImmune is more favorable than Silverback Therapeutics.

NexImmune (NASDAQ:NEXI) and Nurix Therapeutics (NASDAQ:NRIX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, risk, institutional ownership, earnings, dividends and analyst recommendations.

Profitability

This table compares NexImmune and Nurix Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NexImmuneN/AN/AN/A
Nurix TherapeuticsN/AN/AN/A

Analyst Recommendations

This is a summary of current ratings and target prices for NexImmune and Nurix Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NexImmune00303.00
Nurix Therapeutics00603.00

NexImmune presently has a consensus target price of $33.3333, suggesting a potential upside of 78.54%. Nurix Therapeutics has a consensus target price of $46.80, suggesting a potential upside of 64.44%. Given NexImmune's higher probable upside, equities analysts clearly believe NexImmune is more favorable than Nurix Therapeutics.

Earnings and Valuation

This table compares NexImmune and Nurix Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NexImmuneN/AN/AN/AN/AN/A
Nurix TherapeuticsN/AN/AN/AN/AN/A

Insider and Institutional Ownership

82.0% of Nurix Therapeutics shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Nurix Therapeutics beats NexImmune on 2 of the 3 factors compared between the two stocks.

Cricut (NASDAQ:EWTX) and NexImmune (NASDAQ:NEXI) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability and valuation.

Valuation & Earnings

This table compares Cricut and NexImmune's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CricutN/AN/AN/AN/AN/A
NexImmuneN/AN/AN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Cricut and NexImmune, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cricut01302.75
NexImmune00303.00

NexImmune has a consensus price target of $33.3333, suggesting a potential upside of 78.54%. Given NexImmune's stronger consensus rating and higher possible upside, analysts plainly believe NexImmune is more favorable than Cricut.

Profitability

This table compares Cricut and NexImmune's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CricutN/AN/AN/A
NexImmuneN/AN/AN/A

Summary

NexImmune beats Cricut on 2 of the 2 factors compared between the two stocks.

NexImmune (NASDAQ:NEXI) and Kinnate Biopharma (NASDAQ:KNTE) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, valuation and dividends.

Profitability

This table compares NexImmune and Kinnate Biopharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NexImmuneN/AN/AN/A
Kinnate BiopharmaN/AN/AN/A

Earnings & Valuation

This table compares NexImmune and Kinnate Biopharma's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NexImmuneN/AN/AN/AN/AN/A
Kinnate BiopharmaN/AN/AN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings for NexImmune and Kinnate Biopharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NexImmune00303.00
Kinnate Biopharma00403.00

NexImmune presently has a consensus price target of $33.3333, suggesting a potential upside of 78.54%. Kinnate Biopharma has a consensus price target of $52.00, suggesting a potential upside of 92.81%. Given Kinnate Biopharma's higher possible upside, analysts clearly believe Kinnate Biopharma is more favorable than NexImmune.

Summary

Kinnate Biopharma beats NexImmune on 2 of the 2 factors compared between the two stocks.


NexImmune Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
BioAtla logo
BCAB
BioAtla
1.5$47.20+1.5%$1.61 billionN/A0.00
Cullinan Oncology logo
CGEM
Cullinan Oncology
1.3$32.23+0.4%$1.40 billionN/A0.00Analyst Report
News Coverage
Silverback Therapeutics logo
SBTX
Silverback Therapeutics
1.7$35.86+5.3%$1.32 billionN/A0.00
Nurix Therapeutics logo
NRIX
Nurix Therapeutics
1.9$28.89+1.5%$1.30 billionN/A0.00Analyst Downgrade
EWTX
Cricut
1.1$24.96+7.2%$1.27 billionN/A0.00Analyst Report
News Coverage
Gap Up
KNTE
Kinnate Biopharma
1.7$27.46+0.9%$1.20 billionN/A0.00Increase in Short Interest
Vor Biopharma logo
VOR
Vor Biopharma
1.9$26.96+5.9%$1.06 billionN/A0.00
CNTB
Connect Biopharma Holdings Limited American Depositary Shares
1.7$16.96+1.7%$962.29 millionN/A0.00Analyst Report
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.6$24.69+1.6%$882.77 millionN/A0.00
FDMT
4D Molecular Therapeutics
1.3$31.55+4.6%$880.90 millionN/A0.00
Gracell Biotechnologies logo
GRCL
Gracell Biotechnologies
1.5$12.24+4.6%$839.21 millionN/A0.00Gap Up
Pharvaris B.V. logo
PHVS
Pharvaris B.V.
1.4$25.24+3.1%$828.16 millionN/A0.00Gap Down
Pharming Group logo
PHAR
Pharming Group
0.0$12.95+0.9%$827.27 millionN/A0.00
iTeos Therapeutics logo
ITOS
iTeos Therapeutics
1.9$21.91+4.1%$737.78 millionN/A0.00
FNCH
Finch Therapeutics Group
2.0$14.11+9.8%$730.28 millionN/A0.00Analyst Report
News Coverage
Gap Up
ACHL
Achilles Therapeutics plc American Depositary Shares
0.0$15.45+0.4%$630.05 millionN/A0.00
Inventiva logo
IVA
Inventiva
1.4$13.39+0.4%$517.26 millionN/A0.00News Coverage
Gap Down
SGTX
Sigilon Therapeutics
1.4$15.83+1.5%$506.09 millionN/A0.00Gap Up
Gemini Therapeutics logo
GMTX
Gemini Therapeutics
1.7$10.80+3.9%$482.45 millionN/A0.00Gap Up
Landos Biopharma logo
LABP
Landos Biopharma
1.8$10.24+6.0%$435.28 millionN/A0.00Gap Up
Terns Pharmaceuticals logo
TERN
Terns Pharmaceuticals
2.0$16.45+4.0%$429.64 millionN/A0.00Gap Down
Sensei Biotherapeutics logo
SNSE
Sensei Biotherapeutics
2.0$12.75+3.5%$403.76 millionN/A0.00Gap Down
Angion Biomedica logo
ANGN
Angion Biomedica
1.7$12.72+6.7%$400.10 millionN/A0.00Gap Up
PRTG
Portage Biotech
0.0$29.40+8.2%$355.24 millionN/A0.00
Unity Biotechnology logo
UBX
Unity Biotechnology
1.1$4.86+6.8%$283.89 millionN/A-2.59Gap Up
Kaleido Biosciences logo
KLDO
Kaleido Biosciences
1.8$6.20+0.5%$262.02 millionN/A-2.45
Decibel Therapeutics logo
DBTX
Decibel Therapeutics
2.2$9.49+3.7%$245.04 millionN/A0.00
VINC
Vincerx Pharma
1.0$17.01+1.2%$240.80 millionN/A0.00Gap Down
ImmunoPrecise Antibodies logo
IPA
ImmunoPrecise Antibodies
0.0$9.20+7.4%$188.90 millionN/A0.00Increase in Short Interest
News Coverage
LBPH
Longboard Pharmaceuticals
1.9$10.21+0.8%$171.37 millionN/A0.00Quiet Period Expiration
GANX
Gain Therapeutics
1.7$13.60+2.7%$158.29 millionN/A0.00Analyst Report
News Coverage
Gap Down
Annovis Bio logo
ANVS
Annovis Bio
0.0$21.22+3.4%$152.49 millionN/A0.00Gap Up
EVAX
Evaxion Biotech A/S
1.7$6.98+1.9%$131.51 millionN/A0.00
LGVN
Longeveron
0.3$6.26+0.5%$118.10 millionN/A0.00
CMMB
Chemomab Therapeutics
0.0$30.50+13.1%$80.60 millionN/A0.00News Coverage
UPC
Universe Pharmaceuticals
0.0$3.54+0.3%$77.21 millionN/A0.00News Coverage
VRDN
Viridian Therapeutics
1.7$15.04+1.9%$58.78 millionN/A0.00Decrease in Short Interest
Gap Up
Inhibikase Therapeutics logo
IKT
Inhibikase Therapeutics
0.0$5.19+1.0%$52.17 millionN/A0.00
VIRI
Virios Therapeutics
1.3$5.59+0.2%$46.57 millionN/A0.00
VIRX
Viracta Therapeutics
1.7$7.57+0.3%$39.06 millionN/A0.00
VYNT
Vyant Bio
0.0$3.33+3.9%$38.08 millionN/A0.00
NLS Pharmaceutics logo
NLSP
NLS Pharmaceutics
1.7$3.06+4.9%$34.28 millionN/A0.00
VLON
Vallon Pharmaceuticals
0.3$4.39+3.6%$29.90 millionN/A0.00
VRPX
Virpax Pharmaceuticals
0.3$4.15+2.7%$21.07 millionN/A0.00News Coverage
Gap Up
BCTX
BriaCell Therapeutics
0.0$2.87+8.7%$2.41 millionN/A0.00Gap Up
ADiTx Therapeutics logo
ADTX
ADiTx Therapeutics
1.0$2.60+1.5%$0.00N/A0.00
Apotheca Biosciences logo
CBDC
Apotheca Biosciences
0.4$0.08+0.0%$0.00N/A0.00Gap Up
Avid Bioservices logo
CDMOP
Avid Bioservices
0.3$25.06+0.0%$0.00N/A0.00
BMEA
Biomea Fusion
0.0$16.66+2.0%$0.00N/A0.00High Trading Volume
Gap Up
RXRX
Recursion Pharmaceuticals
0.0$31.16+10.1%$0.00N/A0.00High Trading Volume
Gap Up
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.